Literature DB >> 14742677

Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells.

Matjaz Humar1, Soeren E Pischke, Torsten Loop, Alexander Hoetzel, Rene Schmidt, Christoph Klaas, Heike L Pahl, Klaus K Geiger, Benedikt H J Pannen.   

Abstract

Barbiturates are frequently used for the treatment of intracranial hypertension after brain injury but their application is associated with a profound increase in the infection rate. The mechanism of barbiturate-induced failure of protective immunity is still unknown. We provide evidence that nuclear factor of activated T cells (NFAT), an essential transcription factor in T cell activation, is a target of barbiturate-mediated immunosuppression in human T lymphocytes. Treatment of primary CD3+ lymphocytes with barbiturates inhibited the PMA and ionomycin induced increase in DNA binding of NFAT, whereas the activity of other transcription factors, such as Oct-1, SP-1, or the cAMP response element-binding protein, remained unaffected. Moreover, barbiturates suppressed the expression of a luciferase reporter gene under control of NFAT (stably transfected Jurkat T cells), and of the cytokine genes interleukin-2 and interferon-gamma that contain functional binding motifs for NFAT within their regulatory promotor domains (human peripheral blood CD3+ lymphocytes). Neither GABA receptor-initiated signaling nor direct interactions of barbiturates with nuclear proteins affected the activity of NFAT. In contrast, barbiturates suppressed the calcineurin-dependent dephosphorylation of NFAT in intact T cells and also inhibited the enzymatic activity of calcineurin in a cell-free system, excluding upstream regulation. Thus, our results demonstrate a novel mechanism of direct inhibition of the calcineurin/calmodulin complex that may explain some of the known immunosuppressive effects associated with barbiturate treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742677     DOI: 10.1124/mol.65.2.350

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

Review 1.  NFAT as cancer target: mission possible?

Authors:  Jiang-Jiang Qin; Subhasree Nag; Wei Wang; Jianwei Zhou; Wei-Dong Zhang; Hui Wang; Ruiwen Zhang
Journal:  Biochim Biophys Acta       Date:  2014-07-26

2.  γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylation.

Authors:  Niko-Petteri Nykänen; Kai Kysenius; Prasanna Sakha; Päivi Tammela; Henri J Huttunen
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

Review 3.  [Evidence-based intensive care treatment of intracranial hypertension after traumatic brain injury].

Authors:  B H J Pannen; T Loop
Journal:  Anaesthesist       Date:  2005-02       Impact factor: 1.041

4.  Activation, Deficiency, and Reduced IFN-γ Production of Mucosal-Associated Invariant T Cells in Patients with Inflammatory Bowel Disease.

Authors:  Jae Kyun Ju; Young-Nan Cho; Ki-Jeong Park; Han Deok Kwak; Hye-Mi Jin; Seon-Young Park; Hyun Soo Kim; Seung-Jung Kee; Yong-Wook Park
Journal:  J Innate Immun       Date:  2020-06-12       Impact factor: 7.349

5.  Decrease in white blood cell counts after thiopentone barbiturate therapy for refractory intracranial hypertension: A common complication.

Authors:  Shin Yi Ng; Ki Jinn Chin; Tong Kiat Kwek
Journal:  J Neurosci Rural Pract       Date:  2013-08

6.  Comparative biochemical analysis of three members of the Schistosoma mansoni TAL family: Differences in ion and drug binding properties.

Authors:  Charlotte M Thomas; Colin M Fitzsimmons; David W Dunne; David J Timson
Journal:  Biochimie       Date:  2014-11-05       Impact factor: 4.079

7.  Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks.

Authors:  M Manczinger; V Á Bodnár; B T Papp; S B Bolla; K Szabó; B Balázs; E Csányi; E Szél; G Erős; L Kemény
Journal:  Clin Pharmacol Ther       Date:  2017-07-29       Impact factor: 6.875

Review 8.  Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases.

Authors:  Jae-Ung Lee; Li-Kyung Kim; Je-Min Choi
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

9.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

10.  Thiopental inhibits global protein synthesis by repression of eukaryotic elongation factor 2 and protects from hypoxic neuronal cell death.

Authors:  Christian I Schwer; Cornelius Lehane; Timo Guelzow; Simone Zenker; Karl M Strosing; Sashko Spassov; Anika Erxleben; Bernd Heimrich; Hartmut Buerkle; Matjaz Humar
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.